Neuro, The ability to do a bridge financing is quickly slipping away with the share price. A deal at .15 is one thing, but to get $2.5 mil at .05 will cost 50 mil shares plus an equal number of warrants, and the financing entity will then control the company. A convertible note similar to the earlier Samyang deal would also mean loss of control of the company.
Trying to do a partnership deal would be similarly impaired, wouldn't you say? If the entire market cap is $7 mil, who is going to pay $10 or $15 mil in a pharma deal for ADHD/Schizo/Depression?
I hate to say it, but I think our survival options are rapidly slipping away.